Alterity Therapeutics Ltd - ADR

Alterity Therapeutics Ltd. engages in the research and development into Parkinsonian and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Earnings data Q2 2023

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. MSA is a devastating neurodegenerative disorder without approved therapy.

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease

Highlights: NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter patent secures exclusivity for a new class of compounds targeting Parkinson's and Alzheimer's diseases Active investor relations program in Australia and US Cash balance on 31 December 2021 of A$37M MELBOURNE, Australia, Jan. 27, 2022 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2021 (Q2 FY22). The Company's cash position on 31 December 2021 was $37M with operating cash outflows of $4M.

Appendix 4C - Q2 FY22 Quarterly Cash Flow Report

Freeline Therapeutics Holdings

Plus Therapeutics Inc

These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch Right Now That Are Moving in Premarket

MELBOURNE, Australia and SAN FRANCISCO , Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,155,547) to Alterity.

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C.

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

MELBOURNE, Australia, Dec. 14, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has authorized Alterity's Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. "Approval by the New Zealand health authority to proceed with our Phase 2 clinical trial is a significant achievement as it clears the way to initiate the study in the first quarter of next year," said David Stamler, M.D.

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events: MST Financial Lifesciences & Biotech Fourm Wednesday, November 24 th at 5:20 p.m.

Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

MELBOURNE, Australia , Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying video were delivered at the American Autonomic Society 32nd Annual Internation Symposium on the Autonomic Nervous System. The poster, entitled, Cardiovascular safety and pharmacokinetics of ATH434, a novel small molecule inhibitor of α-synuclein aggregation, in adults and older adults, described results from the Company's Phase 1 clinical trial conducted in healthy volunteers.

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

MELBOURNE, Australia, Nov. 5, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studies demonstrating the potential of ATH434 to treat Parkinsonian disorders. Non-motor symptoms (NMS) are common in patients with Parkinsonian disorders, such as Parkinson's disease (PD) and Multiple System Atrophy.

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress.

Appendix 4C - Q1 FY22 Quarterly Cash Flow Report

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced an expansion of the clinical development program for the Company's lead asset, ATH434, in patients with Multiple System Atrophy (MSA), a rare and rapidly progressing Parkinsonian disorder. ATH434 has been shown to reduce abnormal accumulation of α-synuclein by restoring normal iron balance in the brain with the objective of improving motor function in patients with MSA and Parkinson's Disease.

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

MELBOURNE, Australia  and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was presented from the Company's Biomarkers of progression in Multiple System Atrophy (bioMUSE) study at the International Parkinson and Movement Disorder Society Virtual Congress 2021 being held September 17-22, 2021.

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

Alterity has been granted notice of allowance by USPTO for a new group of iron chaperones that redistribute excess iron in neurodegenerative diseases. The Company's iron chaperone technology has decent potential.

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Office  (USPTO) has issued a Notice of Allowance for Alterity's patent application No. 17/239,375.

Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) increased by over 15% pre-market. This is why it happened.

ATHE Stock Price Increases Over 15% Pre-Market: Why It Happened

Highlights: Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model Presents to MST Access Australian Micro & Small Caps Conference Cash balance at 30 June 2021 of A$28M MELBOURNE, Australia, July 30, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2021 (Q4 FY21). The Company's cash position at 30 June 2021 of $28M was bolstered by the receipt of $17M in net proceeds from the use of the company's previously approved "At the Market" facility with shares issued in accordance with ASX Listing Rules 7.1 and 7.1A.

Appendix 4C - Q4 FY21 Quarterly Cash Flow Report

MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that Movement Disorders, the official journal of the International Parkinson and Movement Disorder Society, has published results from a study demonstrating that ATH434 reduces α–synuclein related neurodegeneration in a widely accepted murine model of Multiple System Atrophy (MSA)[1]. "The publication of data demonstrating that ATH434 preserves neurons while reducing α–synuclein in areas of pathology is exactly what we were hoping to see as we advance to clinical trials in MSA," said Alterity Chief Executive Officer David Stamler, M.D.

Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) fell by over 12% pre-market. These are the details.

ATHE Stock Price Falls Over 12% Pre-Market: Details

Alterity Therapeutics Ltd (NASDAQ:ATHE) (ASX:ATH) surged 58% in pre-market trade in New York as the company announced the award of a new patent, which advances its journey towards finding a clinical candidate to treat major neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company has bene granted a new composition of matter patent by the United States Patent and Trademark Office (USPTO).

Alterity Therapeutics shares rise as its new US patent supports bid to find treatment for Alzheimer's and Parkinson's

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) increased by over 60% during intraday trading. This is why it happened.

ATHE Stock Price Increases Over 60%: Why It Happened

MELBOURNE, Australia and SAN FRANCISCO , July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).  The patent secures a broad monopoly over a new class of iron chaperones, a technology capable of redistributing excess iron in the central nervous system.

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's

Highlights: Alterity receives positive guidance from the European Medicines Agency's Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence with Alterity's plan to target early stage MSA patients.

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Highlights: Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research evaluation Strengthening profile at investment, scientific and clinical conferences Dr David Stamler appointed Chief Executive Officer Cash balance as at 31 March 2021 of A$32.8M MELBOURNE, Australia, April 29, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2021 (Q3 FY21).

Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. Data were presented at the American Academy of Neurology virtual annual meeting.

Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder

The stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) increased by over 20% pre-market. This is why it happened.

News for Alterity Therapeutics Ltd - ADR Stock (ATHE)